Home > Insider Trading > Filing (0001562180-20-004454)

Filing Details

Accession Number:: 0001562180-20-004454
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-12 17:19:37
Reporting Period:: 2020-06-10

Accepted Time:: 2020-06-12 17:19:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1704251	John Tilton	C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510	Chief Commercial Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2020-06-10	52,000	$9.29	52,770	No	4	M	Direct
Common Shares	Disposition	2020-06-10	21,364	$66.70	31,406	No	4	S	Direct
Common Shares	Disposition	2020-06-10	22,838	$67.53	8,568	No	4	S	Direct
Common Shares	Disposition	2020-06-10	5,331	$68.57	3,237	No	4	S	Direct
Common Shares	Disposition	2020-06-10	2,467	$69.40	770	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (right to buy)	Disposition	2020-06-10	52,000	$0.00	52,000	$9.29

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
37,292		2027-01-30	No	4	M	Direct

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.05 - $67.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.05 - $68.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.05 - $68.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.05 - $69.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The shares underlying this option vested as to 50% of the shares on January 31, 2017, with the remainder vesting in 2 equal installments on the first and second anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date.